Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting

INTERPACE BIOSCIENCES, INC.

All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.
Series C converts at $2.02/share (date closing price), no liquidation preference, no director designation rights, limited protective provisions.
Series C automatically converts to common upon Nasdaq uplisting; company believes Series C qualifies as stockholders' equity under GAAP.
Amended investor rights agreement provides registration rights; prior support agreement with 1315 Capital terminated.
Exchange is first step toward Nasdaq uplisting; no cash received; additional listing requirements may need to be satisfied.

item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.